drugset / Trial / NCT05169801
To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, double-blind, positive parallel control, multicentre Phase III clinical trial, a clinical trial of biosimilar drugs, so the type of comparison is equivalence test.
Timeline
- Start
- 2018-01-25
- Primary completion
- 2019-10-21
- Completion
- 2021-06-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP102 | Monoclonal antibody | — | — |
| Comparator | Bevacizumab | Monoclonal antibody | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |